Paper Title
The Review on Sumatriptan's Critical Role in Migraine Management
Article Identifiers
Authors
Keywords
Sumatrptan, Migrane, Serotonin, Vasodilation, Vasoconstriction.
Abstract
Sumatriptan, a selective serotonin 5-HT1 receptor agonist, is widely used for the acute treatment of migraine and cluster headaches. This review explores the pharmacological profile, efficacy, safety, and clinical applications of sumatriptan, as well as its role within the broader class of triptans. Sumatriptan’s mechanism of action primarily involves the constriction of cranial blood vessels, inhibition of pro-inflammatory neuropeptide release, and modulation of trigeminal nerve transmission, all of which contribute to its migraine-relieving effects. Clinical trials and meta-analyses consistently demonstrate sumatriptan's efficacy in reducing migraine pain and associated symptoms such as nausea, photophobia, and phonophobia, with faster onset observed in injectable and nasal spray formulations. Common side effects include dizziness, fatigue, and injection site reactions, with cardiovascular concerns limiting its use in certain populations. Advances in triptan formulations and the development of alternative migraine therapies underscore the need for continued assessment of sumatriptan’s comparative effectiveness. This review highlights sumatriptan's critical role in migraine management, its limitations, and future directions for research, especially in terms of improving patient outcomes and expanding treatment options for refractory cases.
Downloads
How To Cite (APA)
Vaishnav U. Parodhe, Chetan G. Vaidya, Komal V. Shende, Dr. Nilesh O. Chachada, & Khushi M. Kongre (November-2024). The Review on Sumatriptan's Critical Role in Migraine Management. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 9(11), d118-d129. https://ijnrd.org/papers/IJNRD2411312.pdf
Issue
Volume 9 Issue 11, November-2024
Pages : d118-d129
Other Publication Details
Paper Reg. ID: IJNRD_302414
Published Paper Id: IJNRD2411312
Downloads: 000121991
Research Area: Pharmacy All
Author Type: Indian Author
Country: Yavatmal, Maharastra, India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2411312.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2411312
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
UGC CARE JOURNAL PUBLICATION | ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Copyright & License
© 2025 — Authors hold the copyright of this article. This work is licensed under a Creative Commons Attribution 4.0 International License. and The Open Definition.
You are free to share, adapt, and redistribute the material, provided proper credit is given to the original author. 🛡️ Disclaimer: The content, data, and findings in this article are based on the authors’ research and have been peer-reviewed for academic purposes only. Readers are advised to verify all information before practical or commercial use. The journal and its editorial board are not liable for any errors, losses, or consequences arising from its use.
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-Reviewed, Refereed, and UGC CARE Journal Publication with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost, and Transparent Peer Review Journal Publication that adheres to the UGC CARE 2025 Peer-Reviewed Journal Policy and aligns with Scopus Journal Publication standards to ensure the highest level of research quality and credibility.
IJNRD offers comprehensive Journal Publication Services including indexing in all major databases and metadata repositories, Digital Object Identifier (Crossref DOI) assignment for each published article with additional fees, citation generation tools, and full Open Access visibility to enhance global research reach and citation impact.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse academic and professional fields. The journal promotes global knowledge exchange among researchers, developers, academicians, engineers, and practitioners, serving as a trusted platform for innovative, peer-reviewed journal publication and scientific collaboration.
Indexing Coverage: Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many other recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
You can now publish your research in IJNRD. IJNRD is a Transparent Peer-Reviewed Open Access Journal Publication (Refereed Journal), aligning with New UGC and UGC CARE recommendations.
For more details, refer to the official notice: UGC Public Notice
Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: November 2025
Current Issue: Volume 10 | Issue 11 | November 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 30-Nov-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
Approval, Licenses and Indexing: More Details
:
